Table 1.
Characteristics | Azathioprine (N=2309) | Mycophenolate mofetil (N=2070) |
---|---|---|
Age – mean ± SD | 36.1 ± 11.8 | 33.4 ± 11.6 |
Female sex – N (%) | 2138 (92.6) | 1857 (89.7) |
Race/Ethnicity | ||
Black | 1089 (47.2) | 925 (44.7) |
White | 579 (25.1) | 506 (24.4) |
Hispanic | 476 (20.6) | 453 (21.9) |
Asian | 93 (4.0) | 114 (5.5) |
American Indian/Alaska Native | 22 (1.0) | 31 (1.5) |
Region – N (%) | ||
Northeast | 523 (22.7) | 577 (27.9) |
South | 837 (36.3) | 680 (32.9) |
Midwest | 378 (16.4) | 368 (17.8) |
West | 571 (24.7) | 445 (21.5) |
Zip code median household income- median $ (25th, 75th) | 41,643 (33,659–51,948) | 42,557 (33,995–55,565) |
Diabetes- N (%) | 297 (12.9) | 242 (11.7) |
SLE risk adjustment index – mean ± SD | 1.4 ± 2.2 | 2.1 ± 2.5 |
Lupus nephritis – N (%) | 503 (21.8) | 1162 (56.1) |
Number of drugs – mean ± SD | 5.0 ± 3.6 | 5.5 ± 3.8 |
Antidepressant use – N (%) | 439 (19.0) | 209 (10.1) |
Corticosteroid use – N (%) | 1898 (82.2) | 1704 (82.3) |
Hydroxychloroquine use – N (%) | 1315 (57.0) | 938 (45.3) |
Immunosuppressant use* - N (%) | 374 (16.2) | 526 (25.4) |
Number of SLE-related laboratory tests+ – mean (SD) | 3.3 (4.2) | 3.71 (5.0) |
Immunosuppressants include methotrexate, leflunomide, tacrolimus, sulfasalazine, cyclosporine, cyclophosphamide, azathioprine (for mycophenolate mofetil initiators) and mycophenolate mofetil (for azathioprine initiators)
Laboratory tests include BUN, creatinine, complement (C3 and C4), ESR, CRP, anti-dsDNA and urinalysis